Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Option exercise | 2 | 492 | |
| Tax withholding / forfeiture | 1 | 89 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
34 Form 4 filings on record, the earliest from Oct 22, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Gregory K. Hinckley - Director | Option exercise | Bio-Rad A Common Stock | 308 | $0.00 | - | |
| Gregory K. Hinckley - Director | Grant or award | Restricted Stock Units | 407 | $0.00 | - | |
| Gregory K. Hinckley - Director | Option exercise | Restricted Stock Units | 308 | $0.00 | - | |
| Jeffrey L. Edwards - Director | Option exercise | Bio-Rad A Common Stock | 308 | $0.00 | - | |
| Jeffrey L. Edwards - Director | Grant or award | Restricted Stock Units | 407 | $0.00 | - | |
| Jeffrey L. Edwards - Director | Option exercise | Restricted Stock Units | 308 | $0.00 | - | |
| Jonathan P. Divincenzo - Officer | Grant or award | Restricted Stock Units | 7,478 | $0.00 | - | |
| Option exercise | Bio-Rad A Common Stock | 1,044 | $0.00 | - | ||
| Tax withholding / forfeiture | Bio-Rad A Common Stock | 335 | $346.37 | $116K | ||
| Option exercise | Restricted Stock Units | 1,044 | $0.00 | - |
This is as far as the anonymous view goes. Create a free account for all 34 BIO filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
BIO-RAD LABORATORIES, INC. (BIO) had 1 insider filing in the last 90 days, with the most recent on 2026-07-28. The full record for BIO runs to 34 Form 4 filings, the earliest from 2024-10-22. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of BIO were filed in the last 90 days.
No insider sales of BIO were filed in the last 90 days. 2 sales are on record for this company.
This page tracks BIO Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add BIO to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.